---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Prekallikrein-directed antisense oligonucleotides"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Prekallikrein-directed antisense oligonucleotides. Topics: Donidalorsen: prophylaxis and dosing interval; Donidalorsen: indication, mechanism, and dosing; Donidalorsen: guideline summary of efficacy by dosing interval. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/prekallikrein-directed-antisense-oligonucleotides"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Prekallikrein-directed antisense oligonucleotides

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Prekallikrein-directed Antisense Oligonucleotides

<a id="topic-2.2.2.1.5-1"></a>

### Donidalorsen: prophylaxis and dosing interval

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE)”
> “every four or eight weeks.”

Source: [FDA Drug Trials Snapshot DAWNZERA](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera)

<a id="topic-2.2.2.1.5-2"></a>

### Donidalorsen: indication, mechanism, and dosing

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.”
> “The recommended dosage of DAWNZERA is 80 mg administered subcutaneously every 4 weeks.”
> “A dosage of 80 mg administered subcutaneously every 8 weeks may be considered.”
> “Donidalorsen lowers PKK concentration, preventing excessive bradykinin production in patients with HAE.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Donidalorsen: guideline summary of efficacy by dosing interval

> “Donidalorsen is an antisense oligonucleotide that blocks the production of prekallikrein in the liver, which is primarily synthesized in the liver.”
> “Efficacy of every 4- and 8-weeks injections was 81% and 55%, respectively, compared to placebo.”
> “Because of a delay in onset of the donidalorsen, when data were compared to placebo starting at week 5, the 4- and 8-weeks dose reduced attacks by 87% and 60%, respectively.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
